Lemildipine

Drug Profile

Lemildipine

Alternative Names: NB 818; NPK 1886

Latest Information Update: 03 Oct 2001

Price : $50

At a glance

  • Originator Banyu
  • Developer Banyu; Kowa
  • Class Antihypertensives; Dihydropyridines; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 03 Oct 2001 No-Development-Reported for Hypertension in Japan (PO)
  • 14 Oct 1999 A study has been added to the pharmacodynamics section
  • 04 Mar 1996 A study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top